SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Grassi, G.
Right arrow Articles by Mancia, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grassi, G.
Right arrow Articles by Mancia, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension

Guido Grassi

Department of Internal Medicine and Cardiovascular Prevention, S Gerardo Hospital, University of Milano-Bicocca, Monza Milan, Center of Clinical Physiology and Hypertension, Milan, Italy, guido.grassi{at}unimib.it

Fosca Quarti-Trevano

Department of Internal Medicine and Cardiovascular Prevention, S Gerardo Hospital, University of Milano-Bicocca, Monza Milan, Center of Clinical Physiology and Hypertension, Milan, Italy

Giuseppe Mancia

Department of Internal Medicine and Cardiovascular Prevention, S Gerardo Hospital, University of Milano-Bicocca, Monza Milan, Center of Clinical Physiology and Hypertension, Milan, Italy

The development of angiotensin II receptor blockers (ARB) as a new class of drugs for the management of hypertension has elicited the attention of many clinicians worldwide with the aim of improving blood pressure (BP) control as well as cardiovascular protection.AmongARB telmisartan has been shown to be characterised by an antihypertensive efficacy fully covering the 24-hour period, thereby allowing to antagonise the adverse effects of early morning BP rise on cardiovascular risk. Other specific effects of the drug are represented by its favourable metabolic profile (particularly on insulin sensitivity) and neutral effects on sympathetic cardiovascular function.These properties are coupled with cardioprotective effects, documented by the evidence that the drug: 1) is effective in favouring the regression of cardiac and vascular organ damage, 2) reduces arterial stiffness and improves vascular distensibility and 3) reverses the endothelial dysfunction typical of the hypertensive state particularly when complicated by renal failure, diabetes, obesity or metabolic syndrome. Several of these properties can account for the results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), documenting the beneficial effects on the drug on cardiovascular morbidity and mortality.

Key Words: angiotensin II receptor antagonists • blood pressure control • cardiac protection • endothelial function • left ventricular hypertrophy • insulin resistance • target organ damage • vascular protection • 24-hour ambulatory blood pressure monitoring

References

  • Battershill AJ, Scott LJ Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. J Hypertens 2007;25:1105-87.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G. Total cardiovascular risk: a new treatment concept. J Hypertens 2006;24(suppl 2):S17-S23.
  • Mancia G., Seravalle G., Grassi G. Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002;20(suppl):S21 -S27.[CrossRef]
  • Mancia G., Grassi G. Systolic and diastolic BP control in antihypertensive drug trials. J Hypertens 2002;20:1461-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G., Pessina AC, Trimarco B., Grassi G. Blood pressure control according to new guidelines targets in lowto high-risk hypertensives managed in specialist practice. J Hypertens 2004;22:2387-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G., Bombelli M., Lanzarotti A. et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002;162:582-6.[Abstract/Free Full Text]
  • Mancia G., Facchetti R., Bombelli M., Grassi G., Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47:846-53.[Abstract/Free Full Text]
  • Mancia G., Parati G., Bilo G. et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens 2007;25:1087-94.[Web of Science][Medline] [Order article via Infotrieve]
  • Gosse P. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc Health Risk Manag 2006;2:195-201.[CrossRef][Medline] [Order article via Infotrieve]
  • Manolis AJ, Reid JL, de Zeeuw D. et al. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. J Hypertens 2004;22:1033-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Neutel J., Smith DH Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5:58-63.[CrossRef][Medline] [Order article via Infotrieve]
  • Calvo C., Hermida RC, Ayala DE, Ruilope LM Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22:837-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parra Carrillo JZ, Fernandez M., Barrera M. et al. Effect of telmisartan 80mg once-daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy. Int J Clin Pract 2004;145(suppl):9-15.
  • Ding PY, Chu KM, Chiang HT, Shu KH A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004;145:16-22.[Medline] [Order article via Infotrieve]
  • Alcocer L., Fernandez-Bonetti P., Campos E. et al. Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study. Int J Clin Pract Suppl 2004;145:23-8.[Medline] [Order article via Infotrieve]
  • Alcocer L., Fernandez-Bonetti P., Campos E. et al. Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004;145:35-9.[Medline] [Order article via Infotrieve]
  • Zhu JR, Bai J., Cai NS et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl 2004;145:46-9.[Medline] [Order article via Infotrieve]
  • Hermida RC, Ayala DE, Fernandez JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007;50:715-22.[Abstract/Free Full Text]
  • Poirier L., de Champlain J., Larochelle P. et al. A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. Blood Press Monit 2004;9:231-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lacourciere Y., Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomised, open-label, blinded-end point (PROBE) trials. Clin Ther 2005;27:1795-805[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nalbantgil I., Nalbantgil S., Ozerkan F. et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004;145:50-4.[Medline] [Order article via Infotrieve]
  • White WB, Lacourciere Y., Davidai G. Effects of the angiotensin II receptor blockers telmisartan vs. valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sharma AM, Davidson J., Koval S., Lacourciere Y. Telmisartan/hydrochlorothiazide vs. valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007;6:28.[CrossRef][Medline] [Order article via Infotrieve]
  • Lacourciere Y., Lenis J., Orchard R. et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998;3:295-302.[Medline] [Order article via Infotrieve]
  • Lacourciere Y., Neutel JM, Davidai G., Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006;19:104-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Neutel JM, Littlejohn TW, Chrysant SG, Singh A.; Telmisartan Study Group. Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005;28:555-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gosse P., Neutel JM, Schumacher H. et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomised clinical trials. Blood Press Monit 2007;12:141-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Derosa G., Cicero AF, Bertone G. et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomised, double-blind study. Clin Ther 2004; 26:1228-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Derosa G., Ragonesi PD, Mugellini A. et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomised, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42:491-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fogari R., Mugellini A., Zoppi A. et al. Effect of telmisartan/hydrochlorothiazide vs. lisinopril/ hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006;20:177-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fogari R., Preti P., Zoppi A. et al. Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am J Hypertens 2005;18:577-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Neldam S., Edwards C.; ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15:151-60.[CrossRef][Medline] [Order article via Infotrieve]
  • Teo K., Yusuf S., Sleight P. et al. Rationale, design, and baseline characteristics of 2 large, simple, randomised trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G., Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol 2000;35(7 suppl 4):S15-S19.[Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G., Bombelli M., Facchetti R. et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007;49:1265-70.[Abstract/Free Full Text]
  • Mancia G., Parati G. The role of blood pressure variability in end-organ damage. J Hypertens Suppl 2003;21:S17-S23.[Medline] [Order article via Infotrieve]
  • Grassi G., Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 2004;43:154-5.[Free Full Text]
  • Julius S., Majahalme S. The changing face of sympathetic overactivity in hypertension. Ann Med 2000;32:365-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Karas M., Lacourciere Y., LeBlanc AR et al. Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens 2005;23:1251-60.[Web of Science][Medline] [Order article via Infotrieve]
  • Fogari R., Preti P., Zoppi A. et al. Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am J Hypertens 2005;18:577-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Somers VK, Dyken ME, Mark AL, Abboud FM Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med 1993;328:303-07.[Abstract/Free Full Text]
  • Kario K. Morning surge and variability in blood pressure: a new therapeutic target? Hypertension 2005;45:485-6.[Free Full Text]
  • Negro R., Hassan H. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. JRAAS 2006;7:243-6. doi:10.3317/jraas.2006.045.[Medline] [Order article via Infotrieve]
  • Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Internal Med 2007;46:1331-6.[CrossRef]
  • Bahadir O., Uzunlulu M., Oguz A., Bahadir MA Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007; 30:49-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grassi G. Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension. J Hypertens 2004;22:1671-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ruilope LM, Rodicio JL Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993;2:962-7.[CrossRef][Medline] [Order article via Infotrieve]
  • Redon J., Williams B. Microalbuminuria in essential hyper-tension: redefining the threshold. J Hypertens 2002;20:353-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mogensen CE Microalbuminuria and hypertension with focus on type 1 and 2 diabetes. J Intern Med 2003;254:45-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Levy D., Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.[Abstract]
  • Levy D., Salomon M., D'Agostino RB et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.[Abstract/Free Full Text]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Muiesan ML, Salvetti M., Paini A. et al. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2007;49:1077-83.[Abstract/Free Full Text]
  • Ruilope LM, Redon J., Schmieder R. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. Vasc Health Risk Manag 2007;3:1-9.[Medline] [Order article via Infotrieve]
  • Bohm M., Lee M., Kreutz R. et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995;13:891-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wagner J., Drab M., Bohlender J. et al. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998;20:205-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lijnen P., Petrov V., Rumilla K., Fagard R. Stimulation of collagen gel contraction by angiotensin II and III in cardiac fibroblasts. JRAAS 2002;3:160-6. doi:10.3317/jraas.2002.036[Medline] [Order article via Infotrieve]
  • Lijnen PJ, Petrov VV, Fagard RH Ang II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via Ang II subtype 1 receptors. JRAAS 2001;2:117-22. doi:10.3317/jraas.2001.012[Medline] [Order article via Infotrieve]
  • Remuzzi A., Remuzzi G. Potential protective effects of telmisartan on renal function deterioration. JRAAS 2006; 7:185-91.doi:10.3317/jraas.2006.036[Medline] [Order article via Infotrieve]
  • Tsunenari I., Ohmura T., Seidler R. et al. Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. JRAAS 2007;8:93-100. doi:10.3317/jraas.2007.017[Medline] [Order article via Infotrieve]
  • Celis SI, Delgado AJ, Galves ES et al. Hemodynamic differences among AT1 receptor blockers in arterial hypertension: results with valsartan and telmisartan. Am J Hypertens 2002;15:72A(abstract).
  • Mattioli AV, Zennaro M., Bonatti S. et al. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004;97:383-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ivanova OV, Fomicheva OA, Sergakova LM et al. Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. J Int Med Res 2005;33 (Suppl 1):21A-29A.[Web of Science][Medline] [Order article via Infotrieve]
  • Conrady AO, Kiselev IO, Usachev NI et al. Effect of 24week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the ACE gene. J Int Med Res 2005;33(suppl 1):30A-38A.[Web of Science][Medline] [Order article via Infotrieve]
  • Petrovic I., Petrovic D., Vukovic N. et al. Ventricular and vascular remodelling effects of the Ang II receptor blocker telmisartan and/or the ACE inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33(suppl 1):39A-49A.[Web of Science][Medline] [Order article via Infotrieve]
  • Mattioli AV, Bonatti S., Monopoli D. et al. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press 2005;14:273-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Galzerano D., Tammaro P., del Viscovo L. et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005;18:1563-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Celik T., Iyisoy A., Kursaklioglu H. et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol 2005;28:298-302.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Friedrich MG, Dahlof B., Sechtem U. et al. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension - a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. JRAAS 2003;4:234-43. doi:10.3317/jraas.2003.038[Medline] [Order article via Infotrieve]
  • Anderson C. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme. J Int Med Res 2005;33(suppl 1):50A-57A.[Web of Science][Medline] [Order article via Infotrieve]
  • Uchida H., Nakamura Y., Kaihara M. et al. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004;27:545-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morimoto S., Yano Y., Maki K., Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006;29:567-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Willum-Hansen T., Staessen JA et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664-70.[Abstract/Free Full Text]
  • Laurent S., Boutouyrie P., Asmar R. et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.[Abstract/Free Full Text]
  • Vingerhoedt NM, Gilles R., Howes JB et al. Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers. JRAAS 2003;4:244-8. doi:10.3317/ jraas.2003.039[Medline] [Order article via Infotrieve]
  • Bellien J., Iacob M., Eltchaninoff H. et al. AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans. Clin Sci 2007;112:393-401.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ceriello A., Piconi L., Esposito K., Giugliano D. Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. Diabetes Care 2007;30:1694-8.[Abstract/Free Full Text]
  • Schmieder RE, Delles C., Mimran A. et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351-6.[Abstract/Free Full Text]
  • Watanabe H., Nakagawa K. Effects of telmisartan on endothelial function and aortic stiffness in patients with morning hypertension and the metabolic syndrome. Circulation 2005;112(suppl 2):608 (abstract).
  • Inoue Y., Ohtani A., Ide H. et al. Angiotensin receptor blocker telmisartan provides earlier improvement in the arterial stifness of essential hypertensives. J Hypertens 2006;24(suppl 6):258(abstract).
  • Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 9, No. 2, 66-74 (2008)
DOI: 10.3317/jraas.2008.017
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Grassi, G.
Right arrow Articles by Mancia, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grassi, G.
Right arrow Articles by Mancia, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement